CY1110516T1 - Αναστρεψιμα απενεργοποιημενη οξινισμενη πλασμινη - Google Patents
Αναστρεψιμα απενεργοποιημενη οξινισμενη πλασμινηInfo
- Publication number
- CY1110516T1 CY1110516T1 CY20091100721T CY091100721T CY1110516T1 CY 1110516 T1 CY1110516 T1 CY 1110516T1 CY 20091100721 T CY20091100721 T CY 20091100721T CY 091100721 T CY091100721 T CY 091100721T CY 1110516 T1 CY1110516 T1 CY 1110516T1
- Authority
- CY
- Cyprus
- Prior art keywords
- present
- acidized
- disabled
- reverse
- plastic
- Prior art date
Links
- 239000003527 fibrinolytic agent Substances 0.000 abstract 3
- 230000003480 fibrinolytic effect Effects 0.000 abstract 3
- 102000001938 Plasminogen Activators Human genes 0.000 abstract 2
- 108010001014 Plasminogen Activators Proteins 0.000 abstract 2
- 229940127126 plasminogen activator Drugs 0.000 abstract 2
- 230000001105 regulatory effect Effects 0.000 abstract 2
- 239000003381 stabilizer Substances 0.000 abstract 2
- 102000012479 Serine Proteases Human genes 0.000 abstract 1
- 108010022999 Serine Proteases Proteins 0.000 abstract 1
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001732 thrombotic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6424—Serine endopeptidases (3.4.21)
- C12N9/6435—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/4833—Thrombin (3.4.21.5)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/482—Serine endopeptidases (3.4.21)
- A61K38/484—Plasmin (3.4.21.7)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/99—Enzyme inactivation by chemical treatment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
- C12Y304/21—Serine endopeptidases (3.4.21)
- C12Y304/21007—Plasmin (3.4.21.7), i.e. fibrinolysin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
Abstract
Η παρούσα εφεύρεση παρέχει μία ινωδολυτική σύνθεση χρήσιμη ως θεραπευτικό παράγοντα για χορήγηση σε έναν ασθενή έχοντα μία θρομβική έμφραξη. Σε μία όψη της παρούσης εφευρέσεως, η ινωδολυτική σύνθεση περιλαμβάνει μία αναστρέψιμα απενεργοποιημένη οξινισμένη πρωτεάση σερίνης αισθητά απαλλαγμένη ενεργοποιητή πλασμινογόνου, ένα ρυθμιστή χαμηλής ρυθμιστικής ικανότητας και προαιρετικά ένα σταθεροποιητικό παράγοντα. Σε μία άλλη όψη της εφευρέσεως, η ινωδολυτική σύνθεση της παρούσης εφευρέσεως περιλαμβάνει μία αναστρέψιμα απενεργοποιημένη οξινισμένη πλασμίνη αισθητά απαλλαγμένη ενεργοποιητή πλασμινογόνου, ένα ρυθμιστή χαμηλής ρυθμιστικής ικανότητας και προαιρετικά ένα σταθεροποιητικό παράγοντα.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/438,331 US6355243B1 (en) | 1999-11-13 | 1999-11-13 | Method of thrombolysis by local delivery of active plasmin |
EP00990910A EP1232252B1 (en) | 1999-11-13 | 2000-11-13 | Reversibly inactivated acidified plasmin |
Publications (1)
Publication Number | Publication Date |
---|---|
CY1110516T1 true CY1110516T1 (el) | 2015-04-29 |
Family
ID=23740237
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101434T CY1108639T1 (el) | 1999-11-13 | 2008-12-10 | Διαδικασια για την παραγωγη μιας συνθεσης αναστρεψιμα αδρανους οξινισμενης πλασμινης |
CY20091100721T CY1110516T1 (el) | 1999-11-13 | 2009-07-07 | Αναστρεψιμα απενεργοποιημενη οξινισμενη πλασμινη |
CY2013030C CY2013030I1 (el) | 1999-11-13 | 2013-07-11 | Αναστρεψιμα απενεργοποιημενη οξινισμενη πλασμινη |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY20081101434T CY1108639T1 (el) | 1999-11-13 | 2008-12-10 | Διαδικασια για την παραγωγη μιας συνθεσης αναστρεψιμα αδρανους οξινισμενης πλασμινης |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CY2013030C CY2013030I1 (el) | 1999-11-13 | 2013-07-11 | Αναστρεψιμα απενεργοποιημενη οξινισμενη πλασμινη |
Country Status (16)
Country | Link |
---|---|
US (6) | US6355243B1 (el) |
EP (4) | EP1232254B1 (el) |
JP (3) | JP5025868B2 (el) |
AT (2) | ATE409222T1 (el) |
AU (3) | AU784534B2 (el) |
BE (1) | BE2013C050I2 (el) |
CA (3) | CA2389337C (el) |
CY (3) | CY1108639T1 (el) |
DE (3) | DE60036017T3 (el) |
DK (2) | DK1232252T3 (el) |
ES (3) | ES2326616T3 (el) |
FR (1) | FR13C0041I2 (el) |
LU (1) | LU92255I2 (el) |
NL (1) | NL300603I2 (el) |
PT (2) | PT1232254E (el) |
WO (3) | WO2001036608A1 (el) |
Families Citing this family (38)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7544500B2 (en) * | 1999-11-13 | 2009-06-09 | Talecris Biotherapeutics, Inc. | Process for the production of a reversibly inactive acidified plasmin composition |
US6355243B1 (en) * | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
US7308303B2 (en) * | 2001-11-01 | 2007-12-11 | Advanced Bionics Corporation | Thrombolysis and chronic anticoagulation therapy |
ES2626268T3 (es) | 2002-09-11 | 2017-07-24 | Chugai Seiyaku Kabushiki Kaisha | Método de purificación de proteínas |
US20040116676A1 (en) * | 2002-09-30 | 2004-06-17 | Hotta Joann | Methods for removal of contaminants from blood product solutions |
GB0228409D0 (en) | 2002-12-06 | 2003-01-08 | Thromb X Nv | Pharmacological vitreolysis |
DK1740698T3 (da) | 2004-04-22 | 2010-10-25 | Talecris Biotherapeutics Inc | Rekombinant modificeret plasmin |
GB0509438D0 (en) * | 2005-05-09 | 2005-06-15 | Prometic Biosciences Ltd | Affinity adsorbets for fibrinogen |
US20060257391A1 (en) * | 2005-05-11 | 2006-11-16 | Bausch & Lomb Incorporated | Non-surgical method for preventing or reducing the rate of the progression of non-proliferative diabetic retinopathy and the treatment of other ocular conditions |
JP2007068497A (ja) * | 2005-09-09 | 2007-03-22 | Nihon Pharmaceutical Co Ltd | プラスミンの精製法 |
US20070134231A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes and compositions thereof |
US20070134230A1 (en) * | 2005-12-13 | 2007-06-14 | Jani Dharmendra M | Method for prolonging activity of autodegradable enzymes |
US20070196350A1 (en) * | 2006-02-22 | 2007-08-23 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
US20070212358A1 (en) * | 2006-03-10 | 2007-09-13 | Bartels Stephen P | Compositions and Methods for Effecting Controlled Posterior Vitreous Detachment |
EP2051732A4 (en) * | 2006-07-26 | 2009-10-21 | Diamedica Inc | DIAGNOSIS AND TREATMENT OF METABOLIC DISORDERS AND METHODS THEREFOR |
EP2220221B1 (en) | 2007-11-29 | 2014-12-31 | Grifols Therapeutics Inc. | Recombinantly modified plasmin |
TWI395593B (zh) | 2008-03-06 | 2013-05-11 | Halozyme Inc | 可活化的基質降解酵素之活體內暫時性控制 |
JP2011522538A (ja) * | 2008-06-04 | 2011-08-04 | タレクリス・バイオセラピユーテイクス・インコーポレーテツド | プラスミン製造のための組成物、方法およびキット |
PT2403865E (pt) | 2009-03-03 | 2015-11-18 | Grifols Therapeutics Inc | Métodos de preparação de plasminogénio |
EP2435562A1 (en) | 2009-05-26 | 2012-04-04 | Biolex Therapeutics, Inc. | Compositions and methods for production of aglycosylated plasminogen |
RU2564131C2 (ru) | 2009-07-10 | 2015-09-27 | ТромбоДженикс НВ | Варианты плазминогена и плазмина |
ES2534911T3 (es) | 2009-08-28 | 2015-04-30 | Thrombogenics N.V. | Uso de plasmina para el tratamiento de fallo de filtración después de trabeculectomía |
RU2525020C2 (ru) * | 2010-03-04 | 2014-08-10 | Грифольс Терапьютикс Инк. | Терапевтические доставочные устройства, системы и способы |
JPWO2012036140A1 (ja) * | 2010-09-14 | 2014-02-03 | 株式会社カネカ | クリングル配列を有する蛋白質またはペプチドを精製または除去するアフィニティ担体、及びそれを用いた精製方法、除去方法 |
BR112013017172A2 (pt) * | 2011-01-05 | 2016-10-11 | Thrombogenics Nv | variantes de plasminogênio e plasmina |
CN102225197B (zh) * | 2011-06-13 | 2013-03-27 | 陕西精健新星生物医药有限公司 | 顶体蛋白的用途及提取方法 |
WO2013024074A1 (en) | 2011-08-12 | 2013-02-21 | Thrombogenics N.V. | Plasminogen and plasmin variants |
US20130315891A1 (en) | 2012-05-25 | 2013-11-28 | Matthew Charles | Formulations of human tissue kallikrein-1 for parenteral delivery and related methods |
CA2880085C (en) | 2012-06-04 | 2021-09-07 | Diamedica Inc. | Human tissue kallikrein 1 glycosylation isoforms |
US9085211B2 (en) * | 2012-09-13 | 2015-07-21 | GM Global Technology Operations LLC | Top mount for strut |
JP5868931B2 (ja) * | 2013-12-05 | 2016-02-24 | 日本食品化工株式会社 | 水溶性食物繊維の安定化方法並びに安定化された水溶性食物繊維組成物およびその製造方法 |
WO2015138507A1 (en) * | 2014-03-11 | 2015-09-17 | Valdemar Portney | Presbyopia correcting wireless optical system |
WO2015169511A2 (de) | 2014-05-06 | 2015-11-12 | Diasys Diagnostic Systems Gmbh | Enzymatische bestimmung von hba1c |
CN106265544B (zh) * | 2016-10-09 | 2019-06-04 | 瑞阳制药有限公司 | 注射用左卡尼汀组合物及其制备方法 |
EP3592377A4 (en) | 2017-03-09 | 2021-02-17 | Diamedica Inc. | DOSAGE FORMS OF TISSUE KALLIKREIN 1 |
CN106913534A (zh) * | 2017-04-27 | 2017-07-04 | 武汉真福医药股份有限公司 | 一种基于重组枯草杆菌纤溶酶的冻干粉针剂及其制备工艺 |
CN107760662B (zh) * | 2017-11-01 | 2021-06-15 | 国药集团武汉血液制品有限公司 | 一种人纤维蛋白溶解酶的制备方法 |
CN107802828B (zh) * | 2017-11-29 | 2018-09-11 | 广东天普生化医药股份有限公司 | 一种激肽释放酶注射液 |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3136703A (en) | 1958-04-22 | 1964-06-09 | Ortho Pharma Corp | Method for obtaining fibrinolysin |
US3066079A (en) * | 1959-09-18 | 1962-11-27 | American Cyanamid Co | Methods for purifying plasminogen |
DK98833C (da) † | 1961-04-25 | 1964-05-25 | Novo Terapeutisk Labor As | Fremgangsmåde til stabilisering af terapeutisk anvendelige plasminopløsninger. |
US3950513A (en) | 1965-12-03 | 1976-04-13 | Novo Terapeutisk Laboratorium A/S | Process of stabilizing therapeutically useful plasmin solutions |
US3434929A (en) | 1966-07-12 | 1969-03-25 | American Cyanamid Co | Process for purifying plasmin |
JPS5137343B2 (el) * | 1972-12-07 | 1976-10-15 | ||
FR2254316B1 (el) * | 1973-12-18 | 1977-04-22 | Choay Sa | |
US3865692A (en) | 1974-01-11 | 1975-02-11 | Abbott Lab | Method for making highly potent plasminogen |
US4177262A (en) | 1974-12-17 | 1979-12-04 | Choay S.A. | Plasminogen compositions containing preactivated plasminogens with or without native plasminogens, process for making same, pharmaceutical compositions and control of blood clots |
US4082612A (en) | 1976-09-24 | 1978-04-04 | Michael Reese Research Foundation | Plasminogen activator complex |
US4259448A (en) * | 1978-01-03 | 1981-03-31 | Nippon Soda Company, Ltd. | Protein adsorbent and process for the purification of urokinase |
JPS5716824A (en) | 1980-07-03 | 1982-01-28 | Green Cross Corp:The | Plasminogen pharmaceutical and stabilizing method thereof |
JPS56106594A (en) | 1980-01-25 | 1981-08-24 | Green Cross Corp:The | Stabilizing method of plasminogen |
US4418052A (en) | 1980-08-12 | 1983-11-29 | Wong Dennis W | Diagnostic compositions and method for radiologic imaging of fibrinogen deposition in the body |
SU1002356A1 (ru) | 1980-12-31 | 1983-03-07 | Всесоюзный кардиологический научный центр АМН СССР | Способ получени иммобилизованного фибринолизина |
GB2090599B (en) * | 1981-01-05 | 1984-06-13 | Novo Industri As | Stabilized plasmin compositions and method for preparation thereof |
IT1194135B (it) * | 1981-01-05 | 1988-09-14 | Novo Industri As | Composizioni di plasmina stabilizzata e metodo per la loro preparazione |
DE3119157A1 (de) | 1981-05-14 | 1982-12-09 | Behringwerke Ag, 3550 Marburg | Verfahren zur herstellung von und danach hergestelltes plasminogen |
US4499073A (en) † | 1981-08-24 | 1985-02-12 | Cutter Laboratories, Inc. | Intravenously injectable immune serum globulin |
US4663146A (en) * | 1983-07-29 | 1987-05-05 | Codon Genetic Engineering Laboratories | Methods and compositions for the diagnosis of bloodclots using plasminogen activator |
GB8334498D0 (en) | 1983-12-24 | 1984-02-01 | Beecham Group Plc | Compounds |
BE904831A (fr) * | 1985-05-28 | 1986-11-27 | Wellcome Found | Composition d'activateur tissulaire du plasminogene. |
ATE142502T1 (de) * | 1986-05-15 | 1996-09-15 | Univ Emory | Injizierbares arzneimittel zum schutz vor gewebebeschädigung durch ischemie |
JP2507339B2 (ja) | 1986-08-11 | 1996-06-12 | 三井東圧化学株式会社 | 粗tPAの精製方法 |
DE3718889A1 (de) * | 1987-06-05 | 1988-12-22 | Behringwerke Ag | Verfahren zur herstellung einer loesung hoher spezifischer volumenaktivitaet von einem protein mit gewebe-plasminogenaktivator (t-pa)-aktivitaet, loesung, enthaltend protein mit t-pa-aktivitaet und verwendung der loesung in der human- und veterinaermedizin |
US4774087A (en) | 1987-08-14 | 1988-09-27 | Northwestern University | Micro-size fibrinolytic plasmin |
AT390801B (de) | 1988-07-28 | 1990-07-10 | Immuno Ag | Verfahren zur herstellung von lys-plasminogen |
JPH0278633A (ja) * | 1988-09-15 | 1990-03-19 | Green Cross Corp:The | ウイルス不活化方法 |
US5024829A (en) * | 1988-11-21 | 1991-06-18 | Centocor, Inc. | Method of imaging coronary thrombi |
US5104651A (en) * | 1988-12-16 | 1992-04-14 | Amgen Inc. | Stabilized hydrophobic protein formulations of g-csf |
RO103682B1 (ro) * | 1989-01-20 | 1992-03-26 | Institutul Cantacuzino | Procedeu de izolare a ceruloplasminei umane |
US5328996A (en) * | 1989-03-29 | 1994-07-12 | University Of Florida Research Foundation, Inc. | Bacterial plasmin receptors as fibrinolytic agents |
US5237050A (en) * | 1989-03-29 | 1993-08-17 | University Of Florida Research Foundation, Inc. | Bacterial plasmin receptors as fibrinolytic agents |
ES2042138T3 (es) * | 1989-05-24 | 1993-12-01 | Miles Inc. | Filtracion en gel del factor viii tratado termicamente. |
DK408289D0 (da) * | 1989-08-18 | 1989-08-18 | Novo Nordisk As | Diagnostisk reagens |
US5017292A (en) * | 1990-05-10 | 1991-05-21 | Millipore Corporation | Membrane, process and system for isolating virus from solution |
AT402367B (de) | 1990-10-11 | 1997-04-25 | Immuno Ag | Pharmazeutische zubereitung auf basis von lys-plasminogen |
JP2500330B2 (ja) | 1991-03-26 | 1996-05-29 | 工業技術院長 | 血栓溶解能を有する生体適合性材料 |
US5288489A (en) * | 1991-08-28 | 1994-02-22 | Orion Therapeutic Systems, Inc. | Fibrinolysis and fibrinogenolysis treatment |
IT1260468B (it) * | 1992-01-29 | 1996-04-09 | Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole | |
AT398004B (de) * | 1992-04-14 | 1994-08-25 | Berbi Gmbh | Verfahren zur bestimmung von plasmin-alpha2- antiplasmin-komplexen unter verwendung eines komplexspezifischen monoklonalen antikörpers |
JP2861655B2 (ja) * | 1992-07-08 | 1999-02-24 | 吉富製薬株式会社 | ヒト尿性トリプシンインヒビター含有液状製剤及びその製造方法 |
US5472692A (en) | 1993-07-02 | 1995-12-05 | New England Deaconess Hospital Corporation | Pro-urokinase mutants |
JPH0739375A (ja) * | 1993-07-29 | 1995-02-10 | Green Cross Corp:The | プラスミノーゲンの精製方法 |
US5407678A (en) * | 1993-09-01 | 1995-04-18 | Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. | Petroleum jelly cream |
US5455338A (en) * | 1993-11-05 | 1995-10-03 | Zymogenetics, Inc. | DNA encoding novel human kunitz-type inhibitors and methods relating thereto |
DE4411143C2 (de) | 1994-03-30 | 1996-08-01 | Immuno Ag | Thrombosemittel |
US5928218A (en) * | 1994-12-16 | 1999-07-27 | Gelbfish; Gary A. | Medical material removal method and associated instrumentation |
US6139819A (en) | 1995-06-07 | 2000-10-31 | Imarx Pharmaceutical Corp. | Targeted contrast agents for diagnostic and therapeutic use |
EP0835931A4 (en) * | 1995-06-26 | 2000-11-15 | Daiichi Pure Chemicals Co Ltd | STABLE PLASMINE SOLUTION |
JP3761925B2 (ja) * | 1995-06-26 | 2006-03-29 | 第一化学薬品株式会社 | 安定なプラスミン溶液 |
JPH099998A (ja) * | 1995-06-26 | 1997-01-14 | Dai Ichi Pure Chem Co Ltd | 安定なプラスミン溶液 |
JP3622286B2 (ja) * | 1995-09-01 | 2005-02-23 | 日東紡績株式会社 | α2 −プラスミンインヒビタ−の測定方法及び測定試 薬 |
EP0843674A1 (en) † | 1995-10-25 | 1998-05-27 | Janssen Pharmaceutica N.V. | Lubeluzole n-oxide |
US6207066B1 (en) * | 1996-07-23 | 2001-03-27 | Nuvue Technologies, L.L.C. | Method for purification of a blood component |
US5767269A (en) * | 1996-10-01 | 1998-06-16 | Hamilton Civic Hospitals Research Development Inc. | Processes for the preparation of low-affinity, low molecular weight heparins useful as antithrombotics |
US6372887B1 (en) * | 1996-11-07 | 2002-04-16 | Heska Corporation | Flea serine protease inhibitor proteins |
EP0860444A1 (en) | 1997-02-24 | 1998-08-26 | Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode Kruis (CLB) | Method for removing viruses from a protein solution |
CN1167823A (zh) * | 1997-03-25 | 1997-12-17 | 黄成已 | 一种含复合活性生物酶保健酒的生产方法 |
US6355243B1 (en) * | 1999-11-13 | 2002-03-12 | Bayer Corporation | Method of thrombolysis by local delivery of active plasmin |
US6969515B2 (en) * | 1999-11-13 | 2005-11-29 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
US6964764B2 (en) * | 1999-11-13 | 2005-11-15 | Talecris Biotherapeutics, Inc. | Method of thrombolysis by local delivery of reversibly inactivated acidified plasmin |
JP2001175386A (ja) * | 1999-12-21 | 2001-06-29 | Fujitsu Ltd | 表示装置及び表示方法並びに記憶媒体 |
US7181417B1 (en) * | 2000-01-21 | 2007-02-20 | Microstrategy, Inc. | System and method for revenue generation in an automatic, real-time delivery of personalized informational and transactional data |
WO2002037319A2 (en) * | 2000-11-01 | 2002-05-10 | Intellocity Usa, Inc. | System and method for rules based media enhancement |
US6978266B2 (en) * | 2001-05-07 | 2005-12-20 | Microsoft Corporation | Determining a rating for a collection of documents |
US7027051B2 (en) * | 2001-06-29 | 2006-04-11 | International Business Machines Corporation | Graphical user interface for visualization of sampled data compared to entitled or reference levels |
US7015911B2 (en) * | 2002-03-29 | 2006-03-21 | Sas Institute Inc. | Computer-implemented system and method for report generation |
US8631142B2 (en) * | 2002-08-07 | 2014-01-14 | International Business Machines Corporation | Inserting targeted content into a portlet content stream |
US6694764B1 (en) | 2003-03-21 | 2004-02-24 | Delphi Technologies, Inc. | Air conditioning system with electric compressor |
US7281202B2 (en) * | 2003-06-19 | 2007-10-09 | Microsoft Corporation | Framework for creating modular web applications |
US6963826B2 (en) * | 2003-09-22 | 2005-11-08 | C3I, Inc. | Performance optimizer system and method |
US7206789B2 (en) * | 2003-11-13 | 2007-04-17 | St. Jude Children's Research Hospital, Inc. | System and method for defining and collecting data in an information management system having a shared database |
US8924869B2 (en) * | 2005-08-12 | 2014-12-30 | Barry Fellman | Service for generation of customizable display widgets |
US7496852B2 (en) * | 2006-05-16 | 2009-02-24 | International Business Machines Corporation | Graphically manipulating a database |
-
1999
- 1999-11-13 US US09/438,331 patent/US6355243B1/en not_active Expired - Lifetime
-
2000
- 2000-11-13 CA CA2389337A patent/CA2389337C/en not_active Expired - Lifetime
- 2000-11-13 ES ES00990910T patent/ES2326616T3/es not_active Expired - Lifetime
- 2000-11-13 WO PCT/US2000/031090 patent/WO2001036608A1/en active Application Filing
- 2000-11-13 AT AT00991956T patent/ATE409222T1/de active
- 2000-11-13 PT PT00991956T patent/PT1232254E/pt unknown
- 2000-11-13 EP EP00991956A patent/EP1232254B1/en not_active Expired - Lifetime
- 2000-11-13 JP JP2001538490A patent/JP5025868B2/ja not_active Expired - Lifetime
- 2000-11-13 AT AT00990910T patent/ATE431401T1/de active
- 2000-11-13 JP JP2001538487A patent/JP2003514789A/ja not_active Withdrawn
- 2000-11-13 WO PCT/US2000/031115 patent/WO2001036609A1/en active IP Right Grant
- 2000-11-13 AU AU30724/01A patent/AU784534B2/en not_active Expired
- 2000-11-13 DE DE60036017.2T patent/DE60036017T3/de not_active Expired - Lifetime
- 2000-11-13 EP EP08010118A patent/EP1956082A1/en not_active Withdrawn
- 2000-11-13 CA CA2389345A patent/CA2389345C/en not_active Expired - Lifetime
- 2000-11-13 ES ES00991956T patent/ES2313912T3/es not_active Expired - Lifetime
- 2000-11-13 DE DE60042214T patent/DE60042214D1/de not_active Expired - Lifetime
- 2000-11-13 DK DK00990910T patent/DK1232252T3/da active
- 2000-11-13 EP EP00978572.6A patent/EP1232251B2/en not_active Expired - Lifetime
- 2000-11-13 CA CA2389487A patent/CA2389487C/en not_active Expired - Lifetime
- 2000-11-13 AU AU16025/01A patent/AU784598B2/en not_active Expired
- 2000-11-13 WO PCT/US2000/042143 patent/WO2001036611A1/en active Application Filing
- 2000-11-13 DK DK00991956T patent/DK1232254T3/da active
- 2000-11-13 ES ES00978572.6T patent/ES2290058T5/es not_active Expired - Lifetime
- 2000-11-13 PT PT00990910T patent/PT1232252E/pt unknown
- 2000-11-13 EP EP00990910A patent/EP1232252B1/en not_active Expired - Lifetime
- 2000-11-13 AU AU36436/01A patent/AU784800B2/en not_active Expired
- 2000-11-13 DE DE60040345T patent/DE60040345D1/de not_active Expired - Lifetime
- 2000-11-13 JP JP2001538488A patent/JP4988115B2/ja not_active Expired - Lifetime
-
2002
- 2002-05-10 US US10/143,156 patent/US20020192794A1/en not_active Abandoned
- 2002-05-10 US US10/143,112 patent/US20030012778A1/en not_active Abandoned
-
2008
- 2008-08-25 US US12/197,617 patent/US7871608B2/en not_active Expired - Fee Related
- 2008-12-10 CY CY20081101434T patent/CY1108639T1/el unknown
-
2009
- 2009-07-07 CY CY20091100721T patent/CY1110516T1/el unknown
-
2013
- 2013-02-07 US US13/761,676 patent/US20130164815A1/en not_active Abandoned
- 2013-02-07 US US13/761,684 patent/US9879246B2/en not_active Expired - Fee Related
- 2013-07-11 CY CY2013030C patent/CY2013030I1/el unknown
- 2013-07-12 FR FR13C0041C patent/FR13C0041I2/fr active Active
- 2013-07-12 NL NL300603C patent/NL300603I2/nl unknown
- 2013-07-17 LU LU92255C patent/LU92255I2/fr unknown
- 2013-07-18 BE BE2013C050C patent/BE2013C050I2/fr unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CY1110516T1 (el) | Αναστρεψιμα απενεργοποιημενη οξινισμενη πλασμινη | |
CY1119168T1 (el) | Φαρμακευτικο παρασκευασμα που περιεχει οξυκωδονη και ναλοξονη | |
DE60331049D1 (de) | Konjugate von zytotoxischen mitteln und biologisch aktiven peptiden | |
TR199801151T2 (xx) | Trombin inhibit�r� �n ila�lar. | |
CY1109972T1 (el) | Χρηση τοξινης αλλαντιασης για τη θεραπευτικη αγωγη του πονου της νεραλγιας | |
ATE334705T1 (de) | Enzymabhängige therapeutische wundverbände | |
CY1108446T1 (el) | Μη νευροτοξικοι παραγοντες ενεργοποιησης πλασμινογονου για την αντιμετωπιση αποπληξιας | |
SE0101932D0 (sv) | Pharmaceutical combinations | |
IT1319202B1 (it) | Farmaci per le malattie a base infiammatoria. | |
ATE187651T1 (de) | Zweikomponenten-fibrinkleber | |
DE60013486D1 (de) | Verbindungen | |
EA200200853A1 (ru) | Применение 2-метилтиазолидин-3,3-дикарбоновой кислоты (2-мтдк) и/или ее физиологически совместимых солей для лечения и/или предупреждения рака | |
BR0012675A (pt) | Uso de inibidores de il-18 | |
EE200300213A (et) | SARP-1 kasutamine sklerodermia raviks ja/või ennetamiseks | |
CY1106363T1 (el) | Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων | |
EA200401454A1 (ru) | Новая комбинация из обратимо действующих ингибиторов протонного насоса и используемых в терапии дыхательных путей лекарственных веществ, предназначенных для лечения респираторных заболеваний | |
SE0300535D0 (sv) | Treatment of burns | |
RU2002128309A (ru) | Полимерная композиция для лечения гнойных ран | |
EP1434590A4 (en) | METHODS OF INHIBITING SERUM FORMATION USING FACTOR XIII |